The role of flu and antipneumococcal vaccinations in preventing exacerbations of asthma and COPD is paramount. Influenza infections and pneumococcal bacteria pose significant risks for respiratory exacerbations in individuals with asthma and COPD. Vaccinations against these pathogens substantially decrease the likelihood of contracting such infections, thereby mitigating both the frequency and severity of exacerbations. Numerous studies have demonstrated the efficacy of these vaccinations in reducing respiratory complications in patients with asthma and COPD. Integrating vaccination strategies into clinical practice is vital for improving the overall management of these chronic respiratory conditions. By doing so, we can alleviate the burden on healthcare systems, enhance patients' quality of life, and reduce morbidity and mortality associated with asthma and COPD exacerbations. The aim of the study is twofold: to raise awareness of anti-flu and pneumococcal vaccination in the general population and in medical scientific public opinion; and to state how vaccination determines a reduction in the rate of bronchitic and pneumonia exacerbation in asthma and COPD.